BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ADMA Biologics (ADMA)ADMA BiologicsEarnings

Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing

Open original release

Related news

ADMAADMA Biologics2026-02-25 21:05 EST

ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

RXRXRecursion2026-02-18 13:30 EST

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

MDXGMiMedx2026-02-17 13:00 EST

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

CHRSCoherus BioSciences, Inc.2026-03-02 14:30 EST

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

CHRSCoherus BioSciences, Inc.2026-03-09 20:15 EST

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

MDXGMiMedx2026-02-25 21:01 EST

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

RXRXRecursion2026-02-25 11:30 EST

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

IBIOIbio Inc2026-05-12 20:05 EST

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

IBIOIbio Inc2026-02-10 21:05 EST

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

View all latest news

ADMA Biologics

ADMA Biologics is a plasma-derived biologics company focused on immunoglobulin therapies and specialty immune products. Its business is centered on plasma supply, manufacturing, and commercial execution.

Recent company news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-03-27 11:00 EST

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

Stock data

Close
8.48 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States